Zydus Lifesciences Limited — Others, 17-04-2025: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

The United States District Court for Delaware upheld the validity of Astellas Pharma Inc.'s patent for the sustained release formulation of mirabegron, marketed as Myrbetriq®. The ruling allows for further litigation on infringement and possible damages to be addressed in a jury trial set for 2026. While there are currently no significant financial implications for Zydus Lifesciences, the company is assessing the order's potential impact on its operations and exploring legal options. This development may foster cautious investor sentiment as the company navigates ongoing legal challenges while preparing for future trials.